Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.40 |
| ▸ | TP53 | P04637 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | UBE2M | P61081 | 1/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | MC5R | P33032 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923892 | 1.00 | MAPT (0.40) | MAPTTP53LMNAHSD11B1UBE2M | |
| SCHEMBL9924259 | 0.90 | CHRM1 (0.38) | MAPTHSD11B1GRM4MC5R | |
| SCHEMBL17206702 | 0.90 | CHRM1 (0.38) | MAPTHSD11B1GRM4MC5R | |
| SCHEMBL9924228 | 0.90 | CHRM1 (0.38) | MAPTHSD11B1GRM4MC5R | |
| SCHEMBL9924084 | 0.89 | GRM4 (0.35) | MAPTTP53LMNAHSD11B1GRM4 | |
| SCHEMBL9924254 | 0.88 | CHRM1 (0.39) | HSD11B1GRM4MC5R | |
| SCHEMBL9924087 | 0.88 | HSD11B1 (0.39) | MAPTLMNAHSD11B1NPSR1GRM4 | |
| SCHEMBL9924255 | 0.87 | GRM4 (0.36) | MAPTHSD11B1GRM4MC5R | |
| SCHEMBL9924077 | 0.86 | GRM4 (0.38) | MAPTLMNAHSD11B1UBE2MDCUN1D1 | |
| SCHEMBL9924256 | 0.85 | NPC1 (0.36) | LMNAGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169199-B2 | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2012078867-A2 | CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |